Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 201–300 of 3,116
Cohen, R. V., Busetto, L., Levinson, R., Le Roux, C. W., Salminen, P., Prager, G., Surgery, I. C. O. T. R. O. O. M. M. I. T. C. O. M. B., Aminian, A., Blüher, M., Carlsson, L., et al. (2024) · British Journal of Surgery · doi:10.1093/bjs/znae283 · Cited by 52
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
“The benefits of GLP-1 medicines have been demonstrated in multiple outcome trials for people with cardiovascular disease 26,106 , peripheral artery disease 30 , liver disease 27 , kidney disease 28 , HFpEF 23,24 and obstructive sleep apnea 34 with multiple new GLP-1 medicines under investigation…”
InfluentialThe Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S., Colhoun, H., Craciun, A.-E., Ezhov, M., Hardt-Lindberg, S., Kleist Jeppesen, O., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.007 · Cited by 51
Self-citationEbrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
Obesity pharmacotherapy in older adults: a narrative review of evidence
Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01529-z · Cited by 51
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management
Gallo, G., Desideri, G., & Savoia, C. (2024) · Nutrients · doi:10.3390/nu16162781 · Cited by 74
Fluid Shear Stress–Regulated Vascular Remodeling: Past, Present, and Future
Deng, H., Eichmann, A., & Schwartz, M. A. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322557 · Cited by 61
Silverii, G. A., Pala, L., Cresci, B., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16076 · Cited by 49
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
Treatment of OSA and its Impact on Cardiovascular Disease, Part 2
Javaheri, S., Javaheri, S., Gozal, D., Campos‐Rodríguez, F., Martínez‐García, M. Á., Mokhlesi, B., Mehra, R., McNicholas, W. T., Somers, V. K., Zee, P. C., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.024 · Cited by 54
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 65
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
Krüger, N., Schneeweiss, S., Desai, R. J., Sreedhara, S. K., Kehoe, A. R., Fuse, K., Hahn, G., Schunkert, H., & Wang, S. V. (2026) · Nature Medicine · doi:10.1038/s41591-025-04102-x · Cited by 48
“Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as key therapies for the treatment of obesity and type 2 diabetes, with several agents demonstrating cardiovascular benefits 7–12 .”
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 160
Self-citationAssociations between Class I, II, or III Obesity and Health Outcomes
Yao, Z., Tchang, B. G., Albert, M. H., Blumenthal, R. S., Nasir, K., & Blaha, M. J. (2025) · NEJM Evidence · doi:10.1056/evidoa2400229 · Cited by 64
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13717 · Cited by 46
Scheen, A. J. (2024) · Drugs · doi:10.1007/s40265-024-02090-9 · Cited by 59
Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01176-6 · Cited by 46
Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024) · Diabetes Care · doi:10.2337/dc24-1082 · Cited by 46
Gabe, M. B. N., Breitschaft, A., Knop, F. K., Hansen, M. R., Kirkeby, K., Rathor, N., & Adrian, C. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15802 · Cited by 46
“14 Oral semaglutide is co-formulated in a tablet with the absorption enhancer N -(8-[hydroxylbenzoyl] amino) caprylate that facilitates absorption across the gastric mucosa, 15 and has been a treatment option for T2D since 2020.”
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 57
Guirguis, E. H., Dougherty, J., Thornby, K., Grace, Y., & Mack, K. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241259528 · Cited by 56
Hurtado, I., Robles, C., Peiró, S., García-Sempere, A., & Sanfélix-Gimeno, G. (2024) · Diabetologia · doi:10.1007/s00125-024-06243-z · Cited by 45
Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
Prevalence and Mortality of Cardiovascular-Kidney-Metabolic Syndrome in China
Zheng, C., Cai, A., Sun, M., Wang, X., Song, Q., Pei, X., Cao, X., Tian, Y., Lip, G. Y. H., Parati, G., et al. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.04.007 · Cited by 69
Huang, Y., Liao, W., Huang, J., Lin, Y., Yang, S., Huang, C., Wang, C., & Su, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15869 · Cited by 44
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Sattar, N. A., & Lee, M. M. Y. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00363-2 · Cited by 58
Sawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 44
Early-onset atherosclerotic cardiovascular disease
Mousavi, I., Suffredini, J. M., Virani, S. S., Ballantyne, C. M., Michos, E. D., Misra, A., Saeed, A., & Jia, X. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae240 · Cited by 62
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Anson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., Wilding, J. P. H., Cuthbertson, D. J., & Alam, U. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102777 · Cited by 44
“The SELECT trial, evaluating semaglutide in obesity without diabetes, re-ported a modest − 0.31% reduction in HbA1c, 24 similar to our fi ndings.”
ResultInfluentialSantos, L. B., Mizubuti, G. B., da Silva, L. M., Silveira, S. Q., Nersessian, R. S. F., Abib, A. D. C. V., Bellicieri, F. N., Lima, H. D. O., Ho, A. M.-H., dos Anjos, G. S., et al. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111668 · Cited by 43
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
Hwang, J. H., Laiteerapong, N., Huang, E. S., Mozaffarian, D., Fendrick, A. M., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.0905 · Cited by 43
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
“This trial indicated that semaglutide was significantly superior to placebos in reducing the occurrence of MACEs (hazard ratio: 0.80; 95% CI: 0.72–0.90; p < 0.001) [62].”
BackgroundInfluentialO'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Calcific aortic stenosis: omics-based target discovery and therapy development
Blaser, M. C., Bäck, M., Lüscher, T. F., & Aikawa, E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae829 · Cited by 45
Lam, C. S. P., Rodríguez, Á., Aminian, A., Ferrannini, E., Heerspink, H. J. L., Jastreboff, A. M., Laffin, L. J., Pandey, A., Ray, K. K., Ridker, P. M., et al. (2025) · Obesity · doi:10.1002/oby.24332 · Cited by 59
Obesity: The Perfect Storm for Heart Failure
Lembo, M., Strisciuglio, T., Fonderico, C., Mancusi, C., Izzo, R., Trimarco, V., Bellis, A., Barbato, E., Esposito, G., Morisco, C., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14641 · Cited by 56
Cesaro, A., Pastori, D., Acerbo, V., Biccirè, F. G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G. Y. H., & Calabrò, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf257 · Cited by 56
COHEN, R. V., Park, J. Y., Prager, G., Bueter, M., le Roux, C. W., Parmar, C. D., Kermansaravi, M., Salminen, P. T. P., & Miras, A. D. (2024) · British journal of surgery · doi:10.1093/bjs/znae284 · Cited by 50
Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 48
The double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 55
Theodorakis, N., & Nikolaou, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010135 · Cited by 50
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 51
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41
First myocardial infarction: risk factors, symptoms, and medical therapy
Nurmohamed, N. S., Ngo‐Metzger, Q., Taub, P. R., Ray, K. K., Figtree, G. A., Bonaca, M. P., Hsia, J. A., Angadageri, S., Earls, J. P., Rodríguez, F., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf390 · Cited by 54
Beavers, K. M., Cortes, T. M., Foy, C. M., Dinkla, L., Reyes San Martin, F., Ard, J. D., Serra, M. C., & Beavers, D. P. (2025) · Obesity · doi:10.1002/oby.24172 · Cited by 41
Reddy, Y. N. V., Frantz, R. P., Hemnes, A. R., Hassoun, P. M., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., Hill, N. S., ERZURUM, S. C., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.530 · Cited by 45
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“GLP-1 RAs reduce the rates of Major Cardiovascular Events (MACE), heart failure, and elicit significant improvements of MASLD, kidney disease and reduce low grade inflammation [13,44].”
InfluentialAlmeida, G. D. O., Nienkotter, T. F., Balieiro, C. C. A., Pasqualotto, E., Cintra, J. B., Carvalho, H. C. P., Silva, A. L. S., Kabariti, J. C., Minucci, B. S., Bertoli, E. D., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00647-3 · Cited by 54
Lassen, M. C. H., Johansen, N. D., Modin, D., Catarig, A., Vistisen, B. K., Amadid, H., Zimmermann, E., Gislason, G., & Biering‐Sørensen, T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15872 · Cited by 40
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment
d’Aiello, A., Filomia, S., Brecciaroli, M., Sanna, T., Pedicino, D., & Liuzzo, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01241-3 · Cited by 52
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
Gorelik, Y., Ghersin, I., Lujan, R., Shlon, D., Loewenberg Weisband, Y., Ben-Tov, A., Matz, E., Zacay, G., Dotan, I., Turner, D., et al. (2025) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae160 · Cited by 41
Park, J. S., Kim, K. S., & Choi, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0106 · Cited by 59
Satti, D. I., Karius, A. K., Chan, J. S. K., Isakadze, N., Yadav, R., Garg, K., Aronis, K. N., Marine, J. E., Berger, R. D., Calkins, H. G., et al. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.03.031 · Cited by 50
Alsaqaaby, M. S., Cooney, S., le Roux, C. W., & Pournaras, D. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00098-6 · Cited by 39
Gasoyan, H., Butsch, W. S., Casacchia, N. J., Schulte, R. J., Criswell, V., Fox, J., Renner, H., Le, P. N. B., Alpert, J. M., & Rothberg, M. B. (2025) · Obesity · doi:10.1002/oby.70058 · Cited by 58
“Treatment with semaglutide also prevents cardiovascular events, particularly in those with obesity and established atherosclerotic cardiovascular disease [6].”
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
Edmonston, D. L., Mulder, H. S., Lydon, E. J., Chiswell, K., Lampron, Z. M., Shay, C. M., Marsolo, K. A., Shah, R. C., Jones, W. S., Gordon, H. S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.016 · Cited by 47
Dermatologic findings associated with semaglutide use: A scoping review
Tran, M. M., Mirza, F. N., Lee, A. C., Goldbach, H. S., Libby, T. J., & Wisco, O. J. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.03.021 · Cited by 51
Billings, L. K., Hsia, S. H., Bays, H. E., Tidemann‐Miller, B., O’Hagan, J., Tham, L. S., Butler, A., KAZDA, C. M., Mather, K. J., & Coşkun, T. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02155-5 · Cited by 47
Able, C. A., Liao, B., Saffati, G., Maremanda, A. P., Applewhite, J., Nasrallah, A. A., Sonstein, J., Alzweri, L. M., & Kohn, T. P. (2024) · International Journal of Impotence Research · doi:10.1038/s41443-024-00895-6 · Cited by 40
Obesity in the Asia-Pacific Region: Current Perspectives
Lui, D. T. W., Ako, J., Dalal, J. J., Fong, A. Y. Y., Fujino, M., Horton, A., Krittayaphong, R., Almahmeed, W. A., Matthias, A. T., Nelson, A. J., et al. (2024) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2023.68 · Cited by 49
Lifestyle interventions for cardiometabolic health
Rutters, F., den Braver, N. R., Lakerveld, J., Mackenbach, J. D., van der Ploeg, H. P., Griffin, S. J., Elders, P. J. M., & Beulens, J. W. J. (2024) · Nature Medicine · doi:10.1038/s41591-024-03373-0 · Cited by 49
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112924 · Cited by 53
Dhatariya, K., Levy, N., Russon, K., Patel, A., Frank, C., Mustafa, O., Newland-Jones, P., Rayman, G., Tinsley, S., & Dhesi, J. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.12.015 · Cited by 37
Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity—Reply
Aronne, L. J., & SURMOUNT-4 Investigators (2024) · JAMA · doi:10.1001/jama.2024.2603 · Cited by 45
Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use
Hurtado, M. D., Tama, E., Fansa, S., Ghusn, W., Añazco, D., Acosta, A. J., Faubion, S. S., & SHUFELT, C. L. (2024) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002310 · Cited by 48
Obesity and Weight Loss Strategies for Patients With Heart Failure
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva‐deAbreu, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.006 · Cited by 47
Wharton, S., le Roux, C. W., Kosiborod, M., Platz, E., Brueckmann, M., Jastreboff, A. M., Hussain, S. A., Pedersen, S. D., Borowska, L., Unseld, A., et al. (2024) · Obesity · doi:10.1002/oby.24184 · Cited by 46
Hosseinpour, A., Sood, A., Kamalpour, J., Zandi, E., Pakmehr, S., Hosseinpour, H., Sood, A., Agrawal, A., & Gupta, R. (2024) · Clinical Cardiology · doi:10.1002/clc.24314 · Cited by 40
Adamou, A. T., Barkas, F., Milionis, H. J., & Ntaios, G. (2024) · International Journal of Stroke · doi:10.1177/17474930241253988 · Cited by 43
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
Kushner, R. F., Ryan, D. H., Deanfield, J., Kokkinos, A., Cercato, C., Wilding, J., Burguera, B., Wu, C., Craciun, A., Pall, D., et al. (2025) · Obesity · doi:10.1002/oby.24222 · Cited by 35
“%] treated with placebo) [8].”
InfluentialSelf-citationWestermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
Survodutide for the Treatment of Obesity
Kosiborod, M., Platz, E., Wharton, S., le Roux, C. W., Brueckmann, M., Hussain, S. A., Unseld, A., Startseva, E., & Kaplan, L. M. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.09.004 · Cited by 42
Karakasis, P., Fragakis, N., Patoulias, D., Theofilis, P., Sagris, Μ., Koufakis, T., Vlachakis, P. K., Rangraze, I. R., El‐Tanani, M., Tsioufis, K. P., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092112 · Cited by 41
Chan, Y.-C., Chuang, S., Kuo, Y., Lian, Y.-Z., & Chen, Y. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.06.083 · Cited by 44
Nelson, L. W., Lee, M. H., Garrett, J. W., Pickhardt, S. G., Warner, J. D., Summers, R. M., & Pickhardt, P. J. (2024) · American Journal of Roentgenology · doi:10.2214/ajr.24.31805 · Cited by 35
Karakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 56
Kommu, S., & Berg, R. L. (2024) · Obesity Reviews · doi:10.1111/obr.13792 · Cited by 50
Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy
Williams, J., Hum, R. M., Rogers, K., Maglio, C., Alam, U., & Zhao, S. S. (2024) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x241271886 · Cited by 39
Perioperative management of patients on glucagon-like peptide-1 receptor agonists
Mizubuti, G. B., Ho, A. M. ‐., da Silva, L. M., & Phelan, R. (2024) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001348 · Cited by 44
Packer, M., Zile, M. R., Kramer, C. M., DiMaria, J. M., Baum, S. J., Litwin, S. E., Murakami, M., Zhou, C., Ou, Y., Koeneman, L., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.06.058 · Cited by 34
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34
Self-citationBrazilian Guidelines of Hypertension – 2025
Brandão, A. A., Rodrigues, C. I. S., Bortolotto, L. A., Armstrong, A. D. C., Mulinari, R. A., Feitosa, A. D. M., Gomes, M. A. M., Barbosa, E. C. D., Moura-Neto, J. A., Neves, M. F., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250624 · Cited by 156
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 38
Stefanou, M.-I., Palaiodimou, L., Theodorou, A., Safouris, A., Fischer, U., Kelly, P. J., Dawson, J., Katan, M., Katsanos, A. H., Lambadiari, V., et al. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241281903 · Cited by 36
Rooney, M. R., Wallace, A. S., Echouffo-Tcheugui, J. B., Fang, M., Hu, J., Lutsey, P. L., Grams, M. E., Coresh, J., & Selvin, E. (2024) · Diabetologia · doi:10.1007/s00125-024-06315-0 · Cited by 45
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
“Recently, semaglutide treatment demonstrated a 1.5% lower risk in absolute risk in the 3P-MACE compared to placebo (6.5% vs. 8.0%, P 0.05) in nondiabetic people with obesity in the Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) trial [72].”
BackgroundInfluentialNeves, J. S., Leite, A. R., Mentz, R. J., Holman, R. R., Zannad, F. M., Butler, J., Packer, M., & Ferreira, J. P. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3478 · Cited by 44
Peripheral Artery Disease: Molecular Mechanisms and Novel Therapies
Athavale, A., Fukaya, E., & Leeper, N. J. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320195 · Cited by 41
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
Dellgren, J. L., Persad, G., & Emanuel, E. J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01356-4 · Cited by 33
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
